OBJECTIVE: To analyze the effect of sociodemographic, disease, and health system characteristics and contextual features about the community of residence on the subsequent initiation of treatment with biologic agents for rheumatoid arthritis (RA). METHODS: We analyzed data from the University of California, San Francisco Rheumatoid Arthritis Panel Study for the years 1999-2011. Principal data collection was by a structured annual phone survey. We estimated Kaplan-Meier curves of the time until initiation of biologic agents, stratified by age and income. We also used Cox regression to estimate the effect of individual-level sociodemographic and medical factors, contextual-level socioeconomic status measures, and density of health providers in the local community on the probability of initiating therapy with biologic agents for RA. RESULTS: In total, 527 persons were included in the panel in 1999, and 229 persons (44%) had initiated therapy with biologic agents by 2011. In multivariable Cox regression models, age <70 years (hazard ratio [HR] for ages 19-54 years 1.89 [95% confidence interval (95% CI) 1.24-2.87] and HR for ages 55-69 years 1.25 [95% CI 0.84-1.87]), Hispanic ethnicity (HR 2.02 [95% CI 1.05-3.86]), household income ≥$30,000/year (HR 1.61 [95% CI 1.12-2.32]), being married or with a partner (HR 1.39 [95% CI 1.00-1.92]), and residence in rural environments (HR 1.96 [95% CI 1.28-2.99]) were associated with a higher probability of initiating biologic agents. Having no (HR 0.18 [95% CI 0.08-0.40]) or only 1-4 rheumatology visits in the year prior to interview (HR 0.60 [95% CI 0.45-0.81]) and living in an area with ≥1 federally qualified health centers (HR 0.63 [95% CI 0.41-0.96]) were associated with a lower probability. CONCLUSION: The probability of initiating therapy with biologic agents is affected by sociodemographic and health system characteristics as well as the nature of the community of residence, resulting in disparities in access to these medications.
OBJECTIVE: To analyze the effect of sociodemographic, disease, and health system characteristics and contextual features about the community of residence on the subsequent initiation of treatment with biologic agents for rheumatoid arthritis (RA). METHODS: We analyzed data from the University of California, San Francisco Rheumatoid Arthritis Panel Study for the years 1999-2011. Principal data collection was by a structured annual phone survey. We estimated Kaplan-Meier curves of the time until initiation of biologic agents, stratified by age and income. We also used Cox regression to estimate the effect of individual-level sociodemographic and medical factors, contextual-level socioeconomic status measures, and density of health providers in the local community on the probability of initiating therapy with biologic agents for RA. RESULTS: In total, 527 persons were included in the panel in 1999, and 229 persons (44%) had initiated therapy with biologic agents by 2011. In multivariable Cox regression models, age <70 years (hazard ratio [HR] for ages 19-54 years 1.89 [95% confidence interval (95% CI) 1.24-2.87] and HR for ages 55-69 years 1.25 [95% CI 0.84-1.87]), Hispanic ethnicity (HR 2.02 [95% CI 1.05-3.86]), household income ≥$30,000/year (HR 1.61 [95% CI 1.12-2.32]), being married or with a partner (HR 1.39 [95% CI 1.00-1.92]), and residence in rural environments (HR 1.96 [95% CI 1.28-2.99]) were associated with a higher probability of initiating biologic agents. Having no (HR 0.18 [95% CI 0.08-0.40]) or only 1-4 rheumatology visits in the year prior to interview (HR 0.60 [95% CI 0.45-0.81]) and living in an area with ≥1 federally qualified health centers (HR 0.63 [95% CI 0.41-0.96]) were associated with a lower probability. CONCLUSION: The probability of initiating therapy with biologic agents is affected by sociodemographic and health system characteristics as well as the nature of the community of residence, resulting in disparities in access to these medications.
Authors: Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301
Authors: Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst Journal: Arthritis Rheum Date: 2008-06-15
Authors: Nakela L Cook; LeRoi S Hicks; A James O'Malley; Thomas Keegan; Edward Guadagnoli; Bruce E Landon Journal: Health Aff (Millwood) Date: 2007 Sep-Oct Impact factor: 6.301
Authors: Gabriela Schmajuk; Sebastian Schneeweiss; Jeffrey N Katz; Michael E Weinblatt; Soko Setoguchi; Jerry Avorn; Raisa Levin; Daniel H Solomon Journal: Arthritis Rheum Date: 2007-08-15
Authors: Soha R Dargham; Sumeja Zahirovic; Mohammed Hammoudeh; Samar Al Emadi; Basel K Masri; Hussein Halabi; Humeira Badsha; Imad Uthman; Ziyad R Mahfoud; Hadil Ashour; Wissam Gad El Haq; Karim Bayoumy; Marianthi Kapiri; Richa Saxena; Robert M Plenge; Layla Kazkaz; Thurayya Arayssi Journal: PLoS One Date: 2018-12-19 Impact factor: 3.240
Authors: Mark Tatangelo; George Tomlinson; J Michael Paterson; Vandana Ahluwalia; Alex Kopp; Tara Gomes; Nick Bansback; Claire Bombardier Journal: JAMA Netw Open Date: 2019-12-02
Authors: Hong J Kan; Kirill Dyagilev; Peter Schulam; Suchi Saria; Hadi Kharrazi; David Bodycombe; Charles T Molta; Jeffrey R Curtis Journal: Arthritis Res Ther Date: 2018-05-02 Impact factor: 5.156